Chinese
英语

Resource Language

资源语种

Publication time

发布时间

Sort By排序

共检索6条数据Total:6

2020-04-13

Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China. liaomy@whu.edu.cn.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. syxiao@uchicago.edu.;Department of Pathology, University of Chicago Medicine, Chicago, IL, 60637, USA. syxiao@uchicago.edu.

Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse

2020-04-13

Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China. liaomy@whu.edu.cn.;Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. syxiao@uchicago.edu.;Department of Pathology, University of Chicago Medicine, Chicago, IL, 60637, USA. syxiao@uchicago.edu.

Data on pathologic changes of the 2019 novel coronavirus disease (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression and fatality, we performed postmortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia. The patients' ages ranged from 59 to 81, including three males and one female. Each patient had at least one underlying disease, including immunocompromised status (chronic lymphocytic leukemia and renal transplantation) or other conditions (cirrhosis, hypertension, and diabetes). Time from disease onset to death ranged from 15 to 52 days. All patients had elevated white blood cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia of type II pneumocytes, all components of diffuse

2020-03-30

Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, 430071,China.;Laboratory Medicine, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.;Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, 430071,China.;Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, 430071,China.;Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China.;Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China.;Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China.;Imaging Department, Zhongnan Hospital, Wuhan University, Wuhan, 430071 China.;Department of Nephrology, Zhongnan Hospital, Wuhan University, Wuhan, 430071,China. Electronic address: shuihua@whu.edu.cn.

In December 2019, an outbreak of coronavirus disease (COVID-19) due to the novel SARS-CoV-2 virus began in China and spread rapidly worldwide. It is unknown whether hemodialysis patients represent a distinct group of patients with certain characteristics that may make them susceptible to infection or severe disease. In this Case Report, we describe the clinical and epidemiological features of COVID-19 in 201 maintenance hemodialysis patients in Zhongnan Hospital of Wuhan university, including 5 maintenance hemodialysis patients who contracted COVID-19 disease. Of the 5 patients with COVID-19, one had a definite history of contact with an infected person. The age range of the patients was 47-67 years. Diarrhea (80%), fever (60%), and fatigue (60%) were the most common symptoms. Lymphopenia occurred in all patients.Chest computerized tomography (CT) scans showed ground glass opacity in the lungs of all patients. Up to February 13, 2020, none of the patients had developed severe

Biological Physics Group, Department of Physics and Astronomy, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Biological Physics Group, Department of Physics and Astronomy, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Textile Technology Group, Department of Materials, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Biological Physics Group, Department of Physics and Astronomy, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Textile Technology Group, Department of Materials, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Textile Technology Group, Department of Materials, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Division of Cancer Studies, School of Biological Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; School of Medicine, University of Nairobi, Nairobi, Kenya.; Division of Medical Education,School of Medical Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.; Biological Physics Group, Department of Physics and Astronomy, School of Natural Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.

Since the outbreak of the COVID-19 pandemic, most countries have recommended their citizens to adopt social distance, hand hygiene, and face mask wearing. However, wearing face masks has not been well adopted by many citizens. While the reasons are complex, there is a general perception that the evidence to support face mask wearing is lacking, especially for the general public in a community setting. Face mask wearing can block or filter airborne virus-carrying particles through the working of colloid and interface science. This paper assesses current knowledge behind the design and functioning of face masks by reviewing the selection of materials, mask specifications, relevant laboratory tests, and respiratory virus transmission trials, with an overview of future development of reusable masks for the general public. This review highlights the effectiveness of face mask wearing in the prevention of COVID-19 infection.CI - © 2021 Elsevier Ltd. All rights reserved.

2021-12-07

National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, China.; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China.; National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China.; Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China.

2021-02-04

Health Management Center, Xiangya Hospital of Central South University, Changsha, China.; Infectious Diseases Hospital of Xuzhou City, Xuzhou, China.; Chest Hospital of Shandong Province, Jinan, China.; The Center for Disease Control and Prevention of Jiangsu Province, Nanjing, China.; Eye Center of Xiangya Hospital, Central South University, Changsha, China.; Department of Clinical Laboratory, the First Hospital of Changsha, Changsha, China.; Department of Clinical Laboratory, the First Hospital of Changsha, Changsha, China.; Department of Clinical Laboratory, the First Hospital of Changsha, Changsha, China.; Health Management Center, Xiangya Hospital of Central South University, Changsha, China.; Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, China.; Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, China.; Sinocare Inc., Changsha, China.; Sinocare Inc., Changsha, China.; Sinocare Inc., Changsha, China.; Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, China.

BACKGROUND: The ongoing coronavirus disease 19 (COVID-19) is posing a threat to the public health globally. Serological test for SARS-CoV-2 antibody can improve early diagnosis of COVID-19 and serves as a valuable supplement to RNA detection. METHOD: A SARS-CoV-2 IgG/IgM combined antibody test strip based on colloidal gold immunochromatography assay was developed, with both spike protein and nucleocapsid protein of SARS-CoV-2 antigen used for antibody detection. From 3 medical institutions across China, serum or plasma of 170 patients with confirmed COVID-19 diagnosis and 300 normal controls were collected and tested with the strip. Sensitivity, specificity, kappa coefficient, receiver operating characteristic (ROC) curve, and area under the curve (AUC) were analyzed. Positive rates in different medical centers, age group, gender, and different disease course were compared. RESULTS: 158 out 170 samples from confirmed COVID-19 patients had positive results from the test, and 296 out of